Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 6/20 | 0.57 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6507338 | 0.87 | LGMN (0.49) | NOTUM | |
| SCHEMBL6502769 | 0.80 | SCN9A (0.59) | NOTUMSCN9AFFAR4PPARA | |
| SCHEMBL31381267 | 0.80 | NOTUM (0.67) | NOTUMACACB | |
| SCHEMBL6506958 | 0.80 | NOTUM (0.85) | NOTUM | |
| SCHEMBL5799166 | 0.76 | NOTUM (0.58) | NOTUM | |
| SCHEMBL6499932 | 0.76 | CYP4F2 (0.61) | NOTUMS1PR5S1PR1 | |
| SCHEMBL15578214 | 0.75 | HTR1A (0.58) | NOTUMS1PR1SCN9AFFAR4 | |
| SCHEMBL5798727 | 0.73 | NOTUM (0.59) | NOTUMFFAR4 | |
| SCHEMBL23381187 | 0.73 | NOTUM (1.00) | NOTUM | |
| SCHEMBL1749207 | 0.72 | NOTUM (0.81) | NOTUMSCN9AFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005019200-A2 | ARYL PIPERIDINE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005019200-A2 | ARYL PIPERIDINE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |